Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Recognized with R&D 100 Award
SANTA CLARA, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Affymetrix, Inc.,
(NASDAQ:AFFX) today announced that the GeneChip(R) Scanner 3000 with AutoLoader
has been selected to receive an R&D 100 Award from R&D Magazine as one of the
100 most technologically significant products of the past year.
The Affymetrix GeneChip Scanner 3000 with AutoLoader is a microarray scanner
designed and produced by the industry pioneer that invented the first
microarray and scanner. This laser scanning, fluorescent confocal microscope
scanner can read Affymetrix GeneChip arrays containing up to 2.5 million
biological features.
This compact bench-top scanner combines easy-to-use features with advanced
optics and solid-state laser technology to provide rapid scan times, enhanced
resolution, high image quality, and data reproducibility for accurate, reliable
results. Its scan rate is about twice that of other systems and it is set up
for automated operation, thereby increasing its overall productivity.
"Affymetrix is honored to be recognized by the R&D Magazine editors and 50
independent judges chosen from the instrument design community," said Tony
McCook, Senior Product Manager, Instrument Systems. "Our commitment to
continuing advances in microarray scanner technology is enabling research that
will help improve people's lives."
The scanner design has laid the foundation for continued evolution of the
GeneChip platform as an integrated genetic analysis system, supporting
continued feature size reduction for higher resolution and greater information
content of microarray-based products.
The GeneChip(R) brand Scanner 3000 with AutoLoader is able to scan 48 catalog
GeneChip arrays, each containing as many as 2.5 million features, in 4.5 hours
or less, depending on the array type scanned. The scanner's ability to read
very small features enables GeneChip arrays to provide entire genomes on one
array. Using the scanner in conjunction with these arrays allows researchers to
perform thousands of simultaneous experiments to determine the genetic makeup
of the sample.
To learn more about the R&D 100 Awards, visit http://www.rdmag.com/
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip(R) brand platform, to address
growing markets focused on understanding the relationship between genes and
human health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing, product
development, market acceptance (including uncertainties relating to product
development and market acceptance of the GeneChip Scanner 3000 with
AutoLoader), personnel retention, uncertainties related to cost and pricing of
Affymetrix products, dependence on collaborative partners, uncertainties
relating to sole source suppliers, uncertainties relating to FDA and other
regulatory approvals, competition, risks relating to intellectual property of
others and the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2003 and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix, Inc.
CONTACT: media, Wes Conard, Assoc. Director, Public Relations,
+1-408-731-5791, or investors, Doug Farrell, Vice President, Investor
Relations, +1-408-731-5285, both of Affymetrix, Inc.
Web site: http://www.rdmag.com/
Web site: http://www.affymetrix.com/